J&J Cancer Drug Combination Shows Low Rates of Treatment-Related Events
New findings indicate Johnson & Johnson's RYBREVANT™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) combination therapy resulted in low rates of treatment-related adverse events.
Johnson & Johnson has presented new findings demonstrating that its combination therapy of RYBREVANT™ (amivantamab and hyaluronidase-lpuj) with LAZCLUZE® (lazertinib) exhibited low rates of treatment-related adverse events. The data was shared at the World Conference on Lung Cancer (WCLC 2026).
The study reported infrequent occurrences of rash, blood clots, and administration-related reactions, suggesting a favorable profile for the subcutaneous delivery method. These outcomes may contribute to improved patient adherence and tolerability compared to other administration routes.
Long-term treatment effects were also assessed. At the one-year mark, fewer than 1% of patients discontinued treatment due to adverse events related to the therapy. This suggests a sustained safety profile over time.
The results build upon survival data from the MARIPOSA study, further supporting the potential of this combination therapy as a treatment option for patients with specific types of lung cancer, while aiming to maintain quality of life.